WO2015120523A1 - Method of detecting cancer - Google Patents

Method of detecting cancer Download PDF

Info

Publication number
WO2015120523A1
WO2015120523A1 PCT/AU2015/050060 AU2015050060W WO2015120523A1 WO 2015120523 A1 WO2015120523 A1 WO 2015120523A1 AU 2015050060 W AU2015050060 W AU 2015050060W WO 2015120523 A1 WO2015120523 A1 WO 2015120523A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cancer
antibody
sample
telomerase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2015/050060
Other languages
English (en)
French (fr)
Inventor
Minesh LALLA
Fabio Turatti
Sharyn WILSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sienna Cancer Diagnostics Ltd
Original Assignee
Sienna Cancer Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014900494A external-priority patent/AU2014900494A0/en
Priority to DK15748774.5T priority Critical patent/DK3108256T3/da
Priority to JP2016550860A priority patent/JP6685229B2/ja
Priority to AU2015218188A priority patent/AU2015218188B2/en
Priority to ES15748774T priority patent/ES2818089T3/es
Priority to EP15748774.5A priority patent/EP3108256B1/en
Application filed by Sienna Cancer Diagnostics Ltd filed Critical Sienna Cancer Diagnostics Ltd
Priority to US15/116,182 priority patent/US10338072B2/en
Priority to CN201580008934.2A priority patent/CN106461666B/zh
Publication of WO2015120523A1 publication Critical patent/WO2015120523A1/en
Priority to IL247270A priority patent/IL247270B/en
Anticipated expiration legal-status Critical
Priority to US16/417,042 priority patent/US11391738B2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G01N2333/9128—RNA-directed DNA polymerases, e.g. RT (2.7.7.49)

Definitions

  • cytological morphological assessment and detection of telomerase can be performed in any order or simultaneously on the same cells.
  • binding of the antibody to one or more bladder epithelial cells indicates that the subject has cancer.
  • an "inconclusive cytological assessment of cell morphology" is one which reveals that one or more clinically relevant cells in a sample obtained from the subject have atypical or indeterminate cytology.
  • samples used in the methods of the present disclosure can be obtained using techniques known in the art.
  • biopsy and resection material can be obtained via cytoscopy.
  • the sample may be obtained via fine needle aspiration.
  • bladder urothelial cells may be obtained from a urine sample supplied by a subject.
  • An "atypical" cytological assessment of cell morphology indicates that cells in the sample have lost their normal appearance but have not reached the level of abnormality of malignant cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
PCT/AU2015/050060 2014-02-17 2015-02-17 Method of detecting cancer Ceased WO2015120523A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN201580008934.2A CN106461666B (zh) 2014-02-17 2015-02-17 检测癌症的方法
JP2016550860A JP6685229B2 (ja) 2014-02-17 2015-02-17 癌を検出する方法
AU2015218188A AU2015218188B2 (en) 2014-02-17 2015-02-17 Method of detecting cancer
ES15748774T ES2818089T3 (es) 2014-02-17 2015-02-17 Procedimiento de detección del cáncer
EP15748774.5A EP3108256B1 (en) 2014-02-17 2015-02-17 Method of detecting cancer
DK15748774.5T DK3108256T3 (da) 2014-02-17 2015-02-17 Fremgangsmåde til detektering af cancer
US15/116,182 US10338072B2 (en) 2014-02-17 2015-02-17 Method of detecting cancer
IL247270A IL247270B (en) 2014-02-17 2016-08-14 Method of detecting cancer
US16/417,042 US11391738B2 (en) 2014-02-17 2019-05-20 Method of detecting cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014900494 2014-02-17
AU2014900494A AU2014900494A0 (en) 2014-02-17 Methods of detecting cancer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/116,182 A-371-Of-International US10338072B2 (en) 2014-02-17 2015-02-17 Method of detecting cancer
US16/417,042 Continuation US11391738B2 (en) 2014-02-17 2019-05-20 Method of detecting cancer

Publications (1)

Publication Number Publication Date
WO2015120523A1 true WO2015120523A1 (en) 2015-08-20

Family

ID=53799455

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2015/050060 Ceased WO2015120523A1 (en) 2014-02-17 2015-02-17 Method of detecting cancer

Country Status (9)

Country Link
US (2) US10338072B2 (https=)
EP (1) EP3108256B1 (https=)
JP (1) JP6685229B2 (https=)
CN (1) CN106461666B (https=)
AU (1) AU2015218188B2 (https=)
DK (1) DK3108256T3 (https=)
ES (1) ES2818089T3 (https=)
IL (1) IL247270B (https=)
WO (1) WO2015120523A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017027928A1 (en) * 2015-08-19 2017-02-23 Sienna Cancer Diagnostics Ltd Cancer detection method

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3108256T3 (da) 2014-02-17 2020-09-21 Sienna Cancer Diagnostics Ltd Fremgangsmåde til detektering af cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002073204A2 (en) * 2001-03-12 2002-09-19 Monogen, Inc Cell-based detection and differentiation of disease states
WO2009075803A2 (en) * 2007-12-05 2009-06-18 The Johns Hopkins University Alternative splice variant patterns of human telomerase reverse transcriptase (htert) in thyroid tumors to distinguish benign from malignant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09262100A (ja) * 1996-03-27 1997-10-07 Mount Sinai School Medicine City Univ New York テロメラーゼ活性の存在を測定することによる尿試料中のヒト膀胱癌細胞の検出方法
ES2360954T3 (es) 2005-02-18 2011-06-10 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Procedimientos para detectar la evolución de la displasia de cuello uterino de bajo grado.
US20090142259A1 (en) * 2006-05-12 2009-06-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
DK3108256T3 (da) 2014-02-17 2020-09-21 Sienna Cancer Diagnostics Ltd Fremgangsmåde til detektering af cancer
US20180238891A1 (en) 2015-08-19 2018-08-23 Sienna Cancer Diagnostics Ltd Cancer Detection Method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002073204A2 (en) * 2001-03-12 2002-09-19 Monogen, Inc Cell-based detection and differentiation of disease states
WO2009075803A2 (en) * 2007-12-05 2009-06-18 The Johns Hopkins University Alternative splice variant patterns of human telomerase reverse transcriptase (htert) in thyroid tumors to distinguish benign from malignant

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DUARTE, M.C. ET AL.: "Expression of TERT in precancerous gastric lesions compared to gastric cancer", BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, vol. 44, no. 2, 2011, pages 100 - 104, XP055219605 *
HIYAMA, E. ET AL.: "Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues", NEOPLASIA, vol. 3, no. 1, 2001, pages 17 - 26, XP002361553, ISSN: 0212-9787 *
KHALBUSS, W. ET AL.: "Immunohistochemical detection of hTERT in urothelial lesions: a potential adjunct to urine cytology", CYTOJOUMAL, vol. 3, no. 1, 2006, pages e18, XP021019245, ISSN: 1742-6413 *
LUZAR, B. ET AL.: "Telomerase catalytic subunit in laryngeal carcinogenesis-an immunohistochemical study", MODEM PATHOLOGY, vol. 18, no. 3, 2005, pages 406 - 411, XP055219602, ISSN: 0893-3952 *
OSAWA, N. ET AL.: "Diagnosis of parathyroid carcinoma using immunohistochemical staining against hTERT", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 24, no. 06, 2009, pages 733 - 741, XP055219596, ISSN: 1107-3756 *
See also references of EP3108256A4 *
ZHAO, P. ET AL.: "Expressions of telomerase reverse transcriptase and fragile histidine triad in human ovarian carcinoma", CHINESE JOURNAL OF CANCER PREVENTION AND TREATMENT (ZHONGLIU FANGZHI ZAZHI, vol. 11, 2004, pages 1278 - 1281 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017027928A1 (en) * 2015-08-19 2017-02-23 Sienna Cancer Diagnostics Ltd Cancer detection method
CN107949791A (zh) * 2015-08-19 2018-04-20 希艾娜癌症诊疗有限公司 癌症检测方法

Also Published As

Publication number Publication date
ES2818089T3 (es) 2021-04-09
US10338072B2 (en) 2019-07-02
DK3108256T3 (da) 2020-09-21
IL247270B (en) 2019-12-31
IL247270A0 (en) 2016-09-29
EP3108256A1 (en) 2016-12-28
CN106461666B (zh) 2020-11-03
AU2015218188B2 (en) 2020-11-05
US20170176438A1 (en) 2017-06-22
JP6685229B2 (ja) 2020-04-22
JP2017505911A (ja) 2017-02-23
CN106461666A (zh) 2017-02-22
AU2015218188A1 (en) 2016-09-15
US11391738B2 (en) 2022-07-19
EP3108256A4 (en) 2017-10-04
US20200049715A1 (en) 2020-02-13
EP3108256B1 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
US12366574B2 (en) Keratin 17 as a biomarker for bladder cancer
Saggiorato et al. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas
EP2329261A1 (en) Prostate cancer biomarker
Courtade‐Saïdi et al. Immunocytochemical staining for p53 and Ki‐67 helps to characterise urothelial cells in urine cytology
US20220381785A1 (en) Cancer Detection Method
US11391738B2 (en) Method of detecting cancer
Chen et al. Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma
Sawczuk et al. DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC
Tiguert et al. New diagnostic and prognostic tools in bladder cancer
JP5574522B2 (ja) 癌マーカー及び癌細胞の検査方法
Kim et al. Cytokeratin 20/p53 dual immunocytochemistry for improving the diagnostic accuracy of urine liquid-based cytology in the detection of urothelial neoplasm: A retrospective study
US20230280345A1 (en) Prediction of response to epidermal growth factor receptor-directed therapies using epiregulin and amphiregulin
Bal et al. The Paris System for Urine Cytology in Urothelial Neoplasms: A Comparative Study with Histopathological Correlation
LOKESHWAR et al. Cytology and tumor markers: Tumor markers beyond cytology

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15748774

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15116182

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016550860

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 247270

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015748774

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015748774

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015218188

Country of ref document: AU

Date of ref document: 20150217

Kind code of ref document: A